These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16989274)

  • 21. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot clinical trial of a near-infrared laser vaccine adjuvant: safety, tolerability, and cutaneous immune cell trafficking.
    Gelfand JA; Nazarian RM; Kashiwagi S; Brauns T; Martin B; Kimizuka Y; Korek S; Botvinick E; Elkins K; Thomas L; Locascio J; Parry B; Kelly KM; Poznansky MC
    FASEB J; 2019 Feb; 33(2):3074-3081. PubMed ID: 30192655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Extended delivery of vaccines to the skin improves immune responses].
    Joyce JC; Sella HE; Jost H; Mistilis MJ; Esser ES; Pradhan P; Toy R; Collins ML; Rota PA; Roy K; Skountzou I; Compans RW; Oberste MS; Weldon WC; Norman JJ; Prausnitz MR
    J Control Release; 2019 Jun; 304():135-145. PubMed ID: 31071375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization.
    Mkrtichyan M; Ghochikyan A; Movsesyan N; Karapetyan A; Begoyan G; Yu J; Glenn GM; Ross TM; Agadjanyan MG; Cribbs DH
    DNA Cell Biol; 2008 Jan; 27(1):19-24. PubMed ID: 17961074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses.
    Fernando GJ; Chen X; Primiero CA; Yukiko SR; Fairmaid EJ; Corbett HJ; Frazer IH; Brown LE; Kendall MA
    J Control Release; 2012 Apr; 159(2):215-21. PubMed ID: 22306334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination.
    Bento D; Staats HF; Borges O
    Vaccine; 2015 Jul; 33(31):3609-13. PubMed ID: 26087299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent insights into cutaneous immunization: How to vaccinate via the skin.
    Engelke L; Winter G; Hook S; Engert J
    Vaccine; 2015 Sep; 33(37):4663-74. PubMed ID: 26006087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].
    Denis F; Alain S; Ploy MC
    Med Sci (Paris); 2007 Apr; 23(4):379-85. PubMed ID: 17433227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal immune responses induced by transcutaneous vaccines.
    Lawson LB; Clements JD; Freytag LC
    Curr Top Microbiol Immunol; 2012; 354():19-37. PubMed ID: 22435116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous immunization: an evolving paradigm in influenza vaccines.
    Gill HS; Kang SM; Quan FS; Compans RW
    Expert Opin Drug Deliv; 2014 Apr; 11(4):615-27. PubMed ID: 24521050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intradermal delivery for vaccine dose sparing: overview of current issues.
    Zehrung D; Jarrahian C; Wales A
    Vaccine; 2013 Jul; 31(34):3392-5. PubMed ID: 23176978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems.
    Wang X; Wang N; Li N; Zhen Y; Wang T
    Hum Vaccin Immunother; 2016 Aug; 12(8):2075-2089. PubMed ID: 27159879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. pH Sensitive phosphorylated chitosan hydrogel as vaccine delivery system for intramuscular immunization.
    Wei J; Xue W; Yu X; Qiu X; Liu Z
    J Biomater Appl; 2017 May; 31(10):1358-1369. PubMed ID: 28387574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine.
    Tozuka M; Oka T; Jounai N; Egawa G; Ishii KJ; Kabashima K; Takeshita F
    J Dermatol Sci; 2016 Apr; 82(1):38-45. PubMed ID: 26674124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies.
    Karande P; Mitragotri S
    Annu Rev Chem Biomol Eng; 2010; 1():175-201. PubMed ID: 22432578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.
    Korkmaz E; Balmert SC; Carey CD; Erdos G; Falo LD
    Expert Opin Drug Deliv; 2021 Feb; 18(2):151-167. PubMed ID: 32924651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in mice.
    Grenfell RF; Shollenberger LM; Samli EF; Harn DA
    Clin Vaccine Immunol; 2015 Mar; 22(3):336-43. PubMed ID: 25609075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural STING Agonist as an "Ideal" Adjuvant for Cutaneous Vaccination.
    Wang J; Li P; Wu MX
    J Invest Dermatol; 2016 Nov; 136(11):2183-2191. PubMed ID: 27287182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: Formulation, physicochemical characterization and immunogenicity assessment.
    Leone M; Priester MI; Romeijn S; Nejadnik MR; Mönkäre J; O'Mahony C; Jiskoot W; Kersten G; Bouwstra JA
    Eur J Pharm Biopharm; 2019 Jan; 134():49-59. PubMed ID: 30453025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Needle-free vaccine delivery.
    Giudice EL; Campbell JD
    Adv Drug Deliv Rev; 2006 Apr; 58(1):68-89. PubMed ID: 16564111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.